<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12078">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00519649</url>
  </required_header>
  <id_info>
    <org_study_id>110474</org_study_id>
    <nct_id>NCT00519649</nct_id>
  </id_info>
  <brief_title>Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.</brief_title>
  <official_title>An Open, Phase IV, Single-group, Multicentre Study to Assess the Long-term Persistence of Antibodies Against Hepatitis B and the Immune Response to a Hepatitis B (HBV) Vaccine Challenge in Children Aged 7-8 Years of Age and Previously Vaccinated in Infancy With GSK Biologicals' HBV Vaccine (Engerix™-B).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the persistence of immunity to hepatitis B in
      children who received three consecutive doses of HBV vaccine (EngerixTM-B) in infancy. The
      Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of Participants With Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations Above the Cut-off Value</measure>
    <time_frame>One month after the challenge dose of HBV vaccine</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anti-HBs antibody cut-off value assessed was 100 milli-international unit per milliliter (mIU/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-HBs Antibody Concentrations Above the Cut-off Value</measure>
    <time_frame>Before challenge dose of HBV vaccine</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anti-HBs antibody cut-off values assessed include 3.3, 10 and 100 mIU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Local Symptoms</measure>
    <time_frame>During the 4-day follow-up period after the challenge dose of HBV vaccine.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed include pain, redness and swelling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited General Symptoms</measure>
    <time_frame>During the 4-day follow-up period after the challenge dose of HBV vaccine.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited general symptoms assessed include fatigue, fever, gastrointestinal symptoms, and headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Unsolicited Adverse Events</measure>
    <time_frame>During the 31-day follow-up period after the challenge dose of HBV vaccine.</time_frame>
    <safety_issue>No</safety_issue>
    <description>An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Serious Adverse Events (SAE)</measure>
    <time_frame>After the challenge dose of HBV vaccine.</time_frame>
    <safety_issue>No</safety_issue>
    <description>An SAE is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">301</enrollment>
  <condition>Hepatitis B Vaccine</condition>
  <arm_group>
    <arm_group_label>Group Engerix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received a single challenge dose of Engerix™ (hepatitis-B [HBV] vaccine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix™-B Kinder</intervention_name>
    <description>Intramuscular injection, 1 dose</description>
    <arm_group_label>Group Engerix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol.

          -  A male or female of 7 to 8 years of age (from and including the 7th birthday up to
             but excluding the 9th birthday) at the time of enrolment.

          -  With documented evidence of previous vaccination with three consecutive doses of
             Engerix™-B in Germany

          -  Written informed consent obtained from the parents or guardians of the subject at the
             time of enrolment.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

        Exclusion Criteria:

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product

          -  Evidence of previous hepatitis B booster vaccination since administration of the
             third dose of Engerix™-B vaccine.

          -  History of or intercurrent hepatitis B disease.

          -  Hepatitis B vaccination at birth.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             during the period starting from 30 days before HBV vaccine challenge and ending 30
             days after.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding HBV vaccine challenge or planned administration during the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the HBV vaccine challenge.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birkenfeld</city>
        <state>Baden-Wuerttemberg</state>
        <zip>75217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ettenheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77955</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Wuerttemberg</state>
        <zip>76189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oberkirch</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77704</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oberstenfeld</city>
        <state>Baden-Wuerttemberg</state>
        <zip>71720</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Offenburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pforzheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>75172</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuttlingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>78532</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bindlach</city>
        <state>Bayern</state>
        <zip>95463</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kaufering</city>
        <state>Bayern</state>
        <zip>86916</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lohr</city>
        <state>Bayern</state>
        <zip>97816</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81735</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tegernsee</city>
        <state>Bayern</state>
        <zip>83684</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Loehne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32584</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minden</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32427</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porta Westfalica</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32457</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankenthal</city>
        <state>Rheinland-Pfalz</state>
        <zip>67227</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trier</city>
        <state>Rheinland-Pfalz</state>
        <zip>54294</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Worms</city>
        <state>Rheinland-Pfalz</state>
        <zip>67547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bredstedt</city>
        <state>Schleswig-Holstein</state>
        <zip>25821</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Flensburg</city>
        <state>Schleswig-Holstein</state>
        <zip>24937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Flensburg</city>
        <state>Schleswig-Holstein</state>
        <zip>24943</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Flensburg</city>
        <state>Schleswig-Holstein</state>
        <zip>24944</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Husum</city>
        <state>Schleswig-Holstein</state>
        <zip>25813</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12679</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13507</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>August 13, 2015</lastchanged_date>
  <firstreceived_date>August 21, 2007</firstreceived_date>
  <firstreceived_results_date>December 17, 2008</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B vaccine</keyword>
  <keyword>Challenge dose</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One additional subject, enrolled but not vaccinated, was not included in the number of subjects under &quot;STARTED&quot;</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group Engerix</title>
          <description>Subjects received a single challenge dose of Engerix™ (hepatitis-B [HBV] vaccine)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group Engerix</title>
          <description>Subjects received a single challenge dose of Engerix™ (hepatitis-B [HBV] vaccine)</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="300"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="7.7" spread="0.46"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="136"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="164"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations Above the Cut-off Value</title>
        <description>Anti-HBs antibody cut-off value assessed was 100 milli-international unit per milliliter (mIU/mL)</description>
        <time_frame>One month after the challenge dose of HBV vaccine</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-to-Protocol (ATP) cohort for analysis of immunogenicity</population>
        <group_list>
          <group group_id="O1">
            <title>Group Engerix</title>
            <description>Subjects received a single challenge dose of Engerix™ (hepatitis-B [HBV] vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="280"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations Above the Cut-off Value</title>
            <description>Anti-HBs antibody cut-off value assessed was 100 milli-international unit per milliliter (mIU/mL)</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="275"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-HBs Antibody Concentrations Above the Cut-off Value</title>
        <description>Anti-HBs antibody cut-off values assessed include 3.3, 10 and 100 mIU/mL</description>
        <time_frame>Before challenge dose of HBV vaccine</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on subjects from the According-to-Protocol cohort for analysis of antibody persistence for whom serological results were available at pre-HBV vaccine challenge blood sampling time point</population>
        <group_list>
          <group group_id="O1">
            <title>Group Engerix</title>
            <description>Subjects received a single challenge dose of Engerix™ (hepatitis-B [HBV] vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="282"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Anti-HBs Antibody Concentrations Above the Cut-off Value</title>
            <description>Anti-HBs antibody cut-off values assessed include 3.3, 10 and 100 mIU/mL</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>&gt;= 3.3 mIU/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="261" lower_limit="44.9" upper_limit="69.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 10 mIU/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="235"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>&gt;= 100 mIU/mL</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling</description>
        <time_frame>During the 4-day follow-up period after the challenge dose of HBV vaccine.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group Engerix</title>
            <description>Subjects received a single challenge dose of Engerix™ (hepatitis-B [HBV] vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="299"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting Solicited Local Symptoms</title>
            <description>Solicited local symptoms assessed include pain, redness and swelling</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="81"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include fatigue, fever, gastrointestinal symptoms, and headache</description>
        <time_frame>During the 4-day follow-up period after the challenge dose of HBV vaccine.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group Engerix</title>
            <description>Subjects received a single challenge dose of Engerix™ (hepatitis-B [HBV] vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="299"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting Solicited General Symptoms</title>
            <description>Solicited general symptoms assessed include fatigue, fever, gastrointestinal symptoms, and headache</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever (Axillary)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gastrointestinal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Unsolicited Adverse Events</title>
        <description>An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>During the 31-day follow-up period after the challenge dose of HBV vaccine.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group Engerix</title>
            <description>Subjects received a single challenge dose of Engerix™ (hepatitis-B [HBV] vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="300"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting Unsolicited Adverse Events</title>
            <description>An Adverse Event is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Serious Adverse Events (SAE)</title>
        <description>An SAE is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
        <time_frame>After the challenge dose of HBV vaccine.</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group Engerix</title>
            <description>Subjects received a single challenge dose of Engerix™ (hepatitis-B [HBV] vaccine)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="300"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting Serious Adverse Events (SAE)</title>
            <description>An SAE is any untoward medical occurrence that:
results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group Engerix</title>
          <description>Subjects received a single challenge dose of Engerix™ (hepatitis-B [HBV] vaccine)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
